

24. (New) A method for detecting a cancerous colon cell comprising:

detecting expression of a gene in a test colon cell, wherein the gene comprises a sequence of

SEQ ID NO:7; and

comparing a level of expression of the gene in the test colon cell with a level of expression of the gene in a control colon cell, wherein the control colon cell is a cancerous colon cell;

wherein where the level of expression of the gene in the test colon cell relative to the level of expression in the control colon cell is similar indicates that the test colon cell is cancerous.

25. (New) The method of claim 24, wherein said detecting is by hybridization.

26. (New) The method of claim 24, wherein said detecting is by PCR amplification.

27. (New) The method of claim 24, wherein the control colon cell is a colon cell of high metastatic potential, and wherein detection of a level of expression of the gene that is higher in the test colon cell than in a control normal cell indicates that the test colon cell is of low metastatic potential. --

## REMARKS

### Formal Matters

Claims 16-27 are pending after entry of the amendments set forth above.

Support for new claims 16-27 is found throughout the specification, including in the claims as originally filed. In particular, support is found in the specification at, for example, page 28, line 23 to page 29, line 16; page 32, lines 6-26; page 32, line 27 to page 36, line 30; page 37, line 18 to page 43, line 7; and page 46, line 12 to page 47, line 4.


No new matter is added.

Applicants expressly reserve the right under 35 USC §121 to file a continuing application directed to the subject matter of the canceled claims during the pendency of this application.

Attached hereto is a marked-up version of the changes made to the specification by the current amendment. The attached page is captioned "Version with markings to show changes made."

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§1.16 and 1.17 which may be required by this paper, or to credit any overpayment, to Deposit Account No. 50-0815.

Respectfully submitted,  
BOZICEVIC, FIELD & FRANCIS LLP

By:   
Carol L. Francis  
Registration No. 36,513

Date: May 10, 2007

BOZICEVIC, FIELD & FRANCIS LLP  
200 Middlefield Road, Suite 200  
Menlo Park, CA 94025  
Telephone: (650) 327-3400  
Facsimile: (650) 327-3231

F:\DOCUMENT\2300\1490CON\text for Prelim am 2300-1490CON.doc

100T-30-421-5860

**"Version with markings to show changes made."**

*Diagnostic and Therapeutic Methods Using Molecules Differentially Expressed in Cancer Cells*

**IN THE SPECIFICATION:**

Paragraph beginning at line1, page 1, has been amended as follows:

This application is a divisional of U.S. application Serial No. 09/400,947, filed September 22, 1999, which [This] application claims the benefit of U.S. Provisional Application No. 60/101,900, filed September 25, 1998, the entirety of which is incorporated herein by reference.

09/400,947, filed September 22, 1999